ProCE Banner Activity


Targeting Rare Genomic Alterations in Advanced Thyroid Cancer: What Endocrinologists Need to Know


Watch this on-demand webcast to get up to date on optimal biomarker testing strategies and personalized therapy in advanced thyroid cancer.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 15, 2023

Expiration: March 14, 2024



Maria E. Cabanillas

Maria E. Cabanillas, MD

Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
Houston, Texas

Lori J. Wirth

Lori J. Wirth, MD

Associate Professor
Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc, Blueprint Medicines and Genentech, a member of the Roche Group, and Lilly.

Bayer HealthCare Pharmaceuticals Inc.

Blueprint Medicines and Genentech, a member of the Roche Group



American Society for Clinical Pathology

ProCE Banner

Partnered with the American Society for Clinical Pathology.

Target Audience

 This program is intended for endocrinologists and other healthcare professionals who care for patients with thyroid cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patients with thyroid cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with thyroid cancer

  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive thyroid cancer and RET inhibition in RET-altered thyroid cancer 

  • Manage treatment-related symptoms associated with the treatment of RET-altered or NTRK fusion–positive cancer

  • Refer eligible patients with NTRK fusion–positive and RET-altered thyroid cancer for ongoing clinical trials


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Maria E. Cabanillas, MD: consultant/advisor/speaker: Bayer, Exelixis, Lilly; researcher: Genentech, Merck.

Lori J. Wirth, MD: consultant/advisor/speaker: Bayer, Coherus, Curie Therapeutics, Eisai, Exelixis, Genentech, Lilly, Merck, Metis Therapeutics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 15, 2023, through March 14, 2024:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the educational activity in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Learners will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.